European Journal of Cancer

European Journal of Cancer RSS feed. The European Journal of Cancer (EJC) is an international multidisciplinary oncology journal, which publishes original research, reviews, and editorial comments on basic and preclinical cancer research, translation

Latest articles

COVID-19 outbreak and Phase 1 trials: should we consider a specific patient management?

The outbreak of the COVID-19 pandemic has deeply challenged health care systems and cancer patients care. Phase 1 studies are among the most complicated clinical trials, and require thorough patient selection as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of Phase 1...

Erratum to ‘Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database’ [European Journal of Cancer, Volume 125 (January 2020) Pages 153–163]

The publisher regrets that the following corrections were missed during the publication of this article.

Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer

We commend authors Owen et al. [1] for their detailed and well-compiled article on oestradiol measurement during fulvestrant treatment for breast cancer. We recorded some similar observations which we have presented as a letter to the Editor [2]. Owing to the word and reference limitation, we were not able to present a detailed literature review of...

RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer

The article by Samuel et al. [1] highlights an important issue of cross-reactivity between the steroidal anti-oestrogen fulvestrant and immunoassays (IAs) for serum oestradiol. The letter should alert oncologists who are not already aware of the issue, which is to be commended. However, we feel the letter did not reflect the preceding literature accurately....

Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36]

The authors regret that they confused the colours of the time-to-progression curves in Figure 4C and Figure 4D. The correct Figure 4 appears below.

Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer

In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their treatments severely disrupted. Patients with cancer were considered at high risk on sparse evidence, and despite a small number of emerging observational...

High dose chemotherapy in a patient with COVID-19

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is an unprecedented challenge [1]. High dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) represents a potentially curative option for testicular germ cell tumor (TGCT) [2], however, to our knowledge, to date there have been no reports...

Impact of the COVID-19 pandemic on cancer treatment: the patients’ perspective

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has inevitable consequences for medical care of non-COVID-19 patients. To assess the impact of this pandemic on oncological care, a nationwide survey was conducted among cancer patients in the Netherlands.

Innovative countermeasures can maintain cancer care continuity during the COVID-19 pandemic in Korea

Even though Korea was known to have the highest number of coronavirus disease 19 (COVID-19) infection in the early phase of the pandemic, Korea was able to successfully flatten the curve in a short period of time without extreme measures. We compared the status of cancer management before and after COVID-19 and analyzed how cancer care continuity was...

Corrigendum to “Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database” [Eur J Canc 125, (January 2020) 153–163]

The authors regret that the affiliation details for Ugo De Giorgi were incomplete in the original publication. The full affiliation is

Discover, share and read the best on the web

Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters! Get unfiltered news feeds or filter them to your liking.

Get Inoreader
Inoreader - Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters!